相似文献
1
CFTR pharmacology.
Cell Mol Life Sci. 2017 Jan;74(1):117-128. doi: 10.1007/s00018-016-2392-x. Epub 2016 Oct 4.
2
CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.
Curr Pharm Des. 2006;12(18):2235-47. doi: 10.2174/138161206777585148.
3
Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas.
Future Med Chem. 2012 Mar;4(3):329-45. doi: 10.4155/fmc.12.1.
4
Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia.
Int J Mol Sci. 2022 Sep 27;23(19):11396. doi: 10.3390/ijms231911396.
5
Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
Int Forum Allergy Rhinol. 2019 Jan;9(1):100-105. doi: 10.1002/alr.22202. Epub 2018 Aug 27.
6
Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
Am J Respir Cell Mol Biol. 2021 May;64(5):604-616. doi: 10.1165/rcmb.2019-0291OC.
7
Ion channels as targets to treat cystic fibrosis lung disease.
J Cyst Fibros. 2018 Mar;17(2S):S22-S27. doi: 10.1016/j.jcf.2017.10.006. Epub 2017 Nov 6.
8
TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis.
Am J Respir Crit Care Med. 2020 Apr 15;201(8):946-954. doi: 10.1164/rccm.201908-1641OC.
9
Gating of CFTR by the STAS domain of SLC26 transporters.
Nat Cell Biol. 2004 Apr;6(4):343-50. doi: 10.1038/ncb1115. Epub 2004 Mar 28.
10
Separating the contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia.
Am J Physiol Lung Cell Mol Physiol. 2021 Dec 1;321(6):L1147-L1160. doi: 10.1152/ajplung.00563.2020. Epub 2021 Oct 20.
引用本文的文献
1
Environment-Associated Variations in Blood Metabolism of Mongolian Cattle Grazing in the Alxa Desert of China.
Vet Sci. 2025 May 21;12(5):506. doi: 10.3390/vetsci12050506.
2
Bayesian Nonparametric Analysis of Residence Times for Protein-Lipid Interactions in Molecular Dynamics Simulations.
J Chem Theory Comput. 2025 Apr 22;21(8):4203-4220. doi: 10.1021/acs.jctc.4c01522. Epub 2025 Apr 2.
3
Bayesian nonparametric analysis of residence times for protein-lipid interactions in Molecular Dynamics simulations.
bioRxiv. 2025 Mar 4:2024.11.07.622502. doi: 10.1101/2024.11.07.622502.
4
The Concise Guide to PHARMACOLOGY 2023/24: Ion channels.
Br J Pharmacol. 2023 Oct;180 Suppl 2(Suppl 2):S145-S222. doi: 10.1111/bph.16178.
5
Oxalate secretion is stimulated by a cAMP-dependent pathway in the mouse cecum.
Pflugers Arch. 2023 Feb;475(2):249-266. doi: 10.1007/s00424-022-02742-3. Epub 2022 Aug 31.
6
Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro.
J Cyst Fibros. 2022 Jul;21(4):637-643. doi: 10.1016/j.jcf.2022.02.011. Epub 2022 Mar 2.
7
Bacterial Membrane Vesicles in Pneumonia: From Mediators of Virulence to Innovative Vaccine Candidates.
Int J Mol Sci. 2021 Apr 8;22(8):3858. doi: 10.3390/ijms22083858.
8
The Application of Bicarbonate Recovers the Chemical-Physical Properties of Airway Surface Liquid in Cystic Fibrosis Epithelia Models.
Biology (Basel). 2021 Mar 29;10(4):278. doi: 10.3390/biology10040278.
9
Drug development in targeting ion channels for brain edema.
Acta Pharmacol Sin. 2020 Oct;41(10):1272-1288. doi: 10.1038/s41401-020-00503-5. Epub 2020 Aug 27.
10
Correctors modify the bicarbonate permeability of F508del-CFTR.
Sci Rep. 2020 May 21;10(1):8440. doi: 10.1038/s41598-020-65287-4.
本文引用的文献
1
Latonduine Analogs Restore F508del-Cystic Fibrosis Transmembrane Conductance Regulator Trafficking through the Modulation of Poly-ADP Ribose Polymerase 3 and Poly-ADP Ribose Polymerase 16 Activity.
Mol Pharmacol. 2016 Aug;90(2):65-79. doi: 10.1124/mol.115.102418. Epub 2016 May 18.
2
Cystic fibrosis.
Lancet. 2016 Nov 19;388(10059):2519-2531. doi: 10.1016/S0140-6736(16)00576-6. Epub 2016 Apr 29.
3
From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations.
Mol Biol Cell. 2016 Feb 1;27(3):424-33. doi: 10.1091/mbc.E14-04-0935.
4
Unravelling druggable signalling networks that control F508del-CFTR proteostasis.
Elife. 2015 Dec 23;4:e10365. doi: 10.7554/eLife.10365.
5
∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.
Nature. 2015 Dec 24;528(7583):510-6. doi: 10.1038/nature15729. Epub 2015 Nov 30.
6
Cystic Fibrosis Transmembrane Conductance Regulator in Sarcoplasmic Reticulum of Airway Smooth Muscle. Implications for Airway Contractility.
Am J Respir Crit Care Med. 2016 Feb 15;193(4):417-26. doi: 10.1164/rccm.201508-1562OC.
7
Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.
Eur J Med Chem. 2015 Jun 24;99:14-35. doi: 10.1016/j.ejmech.2015.05.030. Epub 2015 May 28.
8
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.
9
Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator.
J Med Chem. 2014 Dec 11;57(23):9776-95. doi: 10.1021/jm5012808. Epub 2014 Dec 2.
10
Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation.
Autophagy. 2014;10(11):2053-74. doi: 10.4161/15548627.2014.973737.
Zotero 插件